TT-00973

N/A

Report date: 2026/05/07 20:00:36
NME

Base Information

Drug NameTT-00973
Drug Alias NameTT-00973TT-00973-MSTT-00973MS
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAXL receptor tyrosine kinase inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsAXL receptor tyrosine kinaseTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTransThera Sciences (Nanjing) Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTransThera Sciences (Nanjing) Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A